Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Completed
Regeneron Pharmaceuticals
Phase 2
2011-03-01
Primary Objective:
To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC)
once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma
exacerbation in participants with persistent moderate to severe eosinophilic asthma.
Secondary Objectives:
- To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in
participants with persistent moderate to severe eosinophilic asthma.
- To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in
participants with persistent moderate to severe eosinophilic asthma.
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Completed
Sanofi
Phase 2
2011-03-01
Primary Objective:
To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC)
once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma
exacerbation in participants with persistent moderate to severe eosinophilic asthma.
Secondary Objectives:
- To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in
participants with persistent moderate to severe eosinophilic asthma.
- To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in
participants with persistent moderate to severe eosinophilic asthma.
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
Completed
Sanofi
Phase 1
2011-07-31
The purpose of this study is to assess the safety and tolerability of repeated subcutaneous
(SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
Completed
Regeneron Pharmaceuticals
Phase 1
2011-07-31
The purpose of this study is to assess the safety and tolerability of repeated subcutaneous
(SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
Completed
Sanofi
Phase 2
2012-04-01
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses
of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
